Trial
NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
Entospletinib MM
Why stopped
Sponsor's decision to discontinue development of entospletinib.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-19